Hypertension

An analysis of NHANES data presented at EASD 2021 suggests a return to a healthy weight in patients with obesity could result in reverse some of the cardiovascular risk associated with obesity, including high blood pressure and cholesterol disorders.

Data show the 20-year cumulative incidence of AVR was 3.4% in mild AS, 20.2% in moderate AS, and 54.6% in severe AS.

Research presented at the AHA's Hypertension Scientific Sessions details the increased prevalence of cardiac autonomic neuropathy and decreased survival probability associated with a non-dipping blood pressure at night.

In patients with T2D without prior CVD, chronic kidney disease was the single risk factor associated with highest risk of MACE.

The American Heart Association has released a scientific statement outlining the current knowledge base surrounding potential prevention and treatment strategies for the management of obesity hypertension.

No significant difference in mortality or stroke at 30 days or 1 year was seen in patients who underwent TAVR for bicuspid or tricuspid aortic stenosis.

A total of 269 participants were considered potentially overtreated, while 109 participants were appropriately on target, and 56 participants potentially undertreated.

The potential number of adults projected to be newly eligible for treatment had a range from 643,161 (LVEF, 41% - 50%) to 1,838,756 (LVEF, 41% - 60%).

Overall positive genetic test results for variants was 10.1% for patients diagnosed with AF before 66 years of age and 16.8% in patients diagnosed before 30 years of age.

Intensive systolic blood pressure control led to a large absolute difference in death and HF among patients with abnormal biomarker levels of hscTnT and NTproBNP.

Data show the outcome of all-cause mortality, MI, or stent thrombosis occurred in 5.3% of patients vaccinated against the flu and 7.2% of patients who were given placebo.

Investigators observed systolic blood pressure was lower by a rate of 6.9 mm Hg in the intervention group versus the control group.

Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.

Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.

Data show oral anticoagulation following atrial fibrillation screening was initiated in 1036 participants, with 445 (29.7%) in the ILR group versus 591 (13.1%) in the control group.

Dr. Bhatt discusses the growing field of knowledge surrounding icosapent ethyl treatment in cardiovascular care.

Data from the Salt Substitute and Stroke Study suggest switching from regular salt to a salt substitute could reduce the risk of stroke by 14% and investigators believe these results can be applied to patient populations across the world.

Dr. Bhatt discusses a subgroup analysis of the REDUCE-IT to determine if icosapent ethyl reduced further ischemic events in patients with prior MI.

Globally, 331 million women and 317 million men had hypertension in 1990, compared with 626 million women and 652 million men in 2019.

Pictorial data on carotid intima-media thickness and presence of carotid plaques can improve prescription of lipid-lowering drugs.

There was little difference in hospitalization and mortality rates between vaccinated schizophrenia patients and vaccinated control patients.

Data show the change in 24-hour ambulatory systolic blood pressure was significant between treatment and control groups with a reduction of 7.1 mm Hg.

Kelly Chin, MD discusses the recent FDA approval of selexipag IV and breakthroughs in the cardiovascular care space.

A retrospective cohort study with data from nearly 4 million patients with hypertension from the US, Germany, and South Korea found ACEs and ARBs provide similar efficacy for prevention of cardiovascular events, but ACEs were associated with a greater risk of adverse events.

A meta-analysis of 14 studies suggests use of antihypertensive agents known to cross the blood-brain barrier was associated with improved memory recall over time compared to nonpenetrant agents in older adults with hypertension.

Data show HDP occurred in 7.4% of pregnancies in France during the study period.

The AHA has released a scientific statement highlighting the importance of prescribing physical activity as a first-line treatment in patient populations with elevated blood pressure or elevated cholesterol.

New observational data from the SPRINT trial provides further support of using a more intense blood pressure goal, suggesting use of 120 mmHg as a goal rather than 140 mmHg could reduce the risk of major adverse cardiovascular events.

An analysis of patients who achieved blood pressure goal within a digital care program details the potential ability of digital health interventions to improve management of patients with hypertension.

Results of RADIANCE-HTN TRIO suggest ultrasound renal denervation could improve blood pressure control in patients with refractory hypertension, suggesting RDN was associated with a mean reduction of 8 mmHg from baseline a 4.5 mmHg improvement over sham procedure.